SHARE

According to the recently published report ‘Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Pipeline Review, H2 2017’; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report ‘Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) – Pipeline Review, H2 2017’ outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Psychiatric Disorders, Smoking Addiction, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Major Depressive Disorder, Neurology, Nicotine Addiction and Pain.

Complete research report on Arterial Thrombosis- Pipeline is available at:

https://www.marketinsightsreports.com/reports/0115155431/neuronal-acetylcholine-receptor-subunit-alpha-4-chrna4-pipeline-review-h2-2017

Scope:

– The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
– The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
– The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

For Any queries feel free to reach us at: https://www.marketinsightsreports.com/reports/0115155431/neuronal-acetylcholine-receptor-subunit-alpha-4-chrna4-pipeline-review-h2-2017/inquiry

Reasons to buy:

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Drug Profiles : 

AAT-008, AN-3485, BBI-2000, EB-01, EB-05 , grapiprant, HPT-721, NCT-10004, pertussis [strain BPZE1] vaccine, secukinumab, SIG-1322, WOL-071007

Drug Profiles : 

BIX-01294, CM-272, EZM-8266, Small Molecules to Inhibit G9a for Breast Cancer, Small Molecules to Inhibit G9a for Oncology, TM-2115, verticillin A.

Companies Involved in Therapeutics Development are :

Domainex Ltd., Epizyme Inc.

 

About Us:

MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more.

For more information contact at sales@marketinsightsreports.com or call us at +1 (704) 266-3234

Connect With us On: 

https://www.linkedin.com/company/13411016/

https://www.facebook.com/marketinsightsreports/

https://twitter.com/MIRresearch